EU and US could reach trade deal this weekend - Reuters
On Thursday, Cantor Fitzgerald reiterated its Overweight rating on BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN) with a steady price target of $90.00. According to InvestingPro analysis, the stock appears undervalued at current levels, with strong fundamentals supporting potential upside. The firm’s analysis indicates that while BioMarin needs to further assure investors about the longevity of its drug Voxzogo, the provided guidance for 2025 suggests strong growth potential for the company. BioMarin’s revenue is expected to increase by 9-12% year-over-year, reaching $3.1 billion to $3.2 billion, which is above the consensus estimate of $3.095 billion.
The company’s earnings are also projected to show significant growth, with an anticipated increase of 20-25% year-over-year to $4.20-4.40 per share, surpassing the consensus forecast of $4.15. This growth is attributed to the expanding operating margins, which are expected to reach 32-33% in 2025, compared to the consensus of 32%, with a target of 40% operating margin by 2026.
BioMarin’s financial outlook is further bolstered by its 2024 operating margin performance, which was reported at 28.6%, exceeding the initial guidance range of 23-24%. This improvement in operating margins reflects the company’s increasing profitability and efficient management of its operations.
The positive guidance provided by BioMarin for the upcoming years is set to inject new vitality into the company’s stock. With these robust growth figures and expanding margins, BioMarin appears to be on a trajectory to strengthen its financial position in the biopharmaceutical industry. InvestingPro subscribers can access additional insights through the comprehensive Pro Research Report, which includes detailed analysis of BioMarin’s growth prospects and financial metrics.
In other recent news, BioMarin Pharmaceutical Inc. reported impressive fourth-quarter results, with adjusted earnings per share of $0.92, significantly exceeding the analyst consensus of $0.55. The company’s revenue for the quarter was $747 million, surpassing estimates of $711.42 million and marking a 16% increase year-over-year. BioMarin’s strong performance was largely driven by robust demand for its rare disease treatments, particularly VOXZOGO, which saw a 42% year-over-year sales increase to $208 million in Q4. Looking ahead, BioMarin provided an optimistic forecast for 2025, expecting full-year revenue between $3.1 billion and $3.2 billion, alongside adjusted earnings per share projected to be $4.20-$4.40, above analysts’ expectations.
Piper Sandler raised its price target for BioMarin shares to $126 from $122, maintaining an Overweight rating, citing the company’s impressive financial performance and promising guidance for 2025. Stifel also increased its price target to $91 from $89, with a Buy rating, highlighting the notable 50% year-over-year revenue growth of VOXZOGO. Meanwhile, BMO Capital Markets maintained its $115 price target and Outperform rating, emphasizing BioMarin’s strong quarterly performance and potential upside in 2025.
These developments reflect a growing confidence among analysts in BioMarin’s financial targets and strategic plans. The company anticipates advancing several pipeline candidates in 2025, including potential treatments for Duchenne muscular dystrophy and multiple skeletal conditions. Despite some investor skepticism, analysts believe BioMarin’s market value is poised for reevaluation as it continues to deliver on its strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.